Do cholinesterase inhibitors decrease long-term cognitive decline and risk of death in patients with Alzheimer dementia?
Cholinesterase inhibitors, particularly galantamine, are associated with decreased long-term cognitive decline, risk of severe dementia, and mortality in patients with Alzheimer dementia.
This study provides Class III evidence that for patients with Alzheimer dementia ChEIs decrease long-term cognitive decline and risk of death and that galantamine decreases the risk of severe dementia.
Xu et al. (Fri,) studied this question.